Effect of tolterodine on sleep structure modulated by CYP2D6 genotype

Sleep Medicine

Volumn 9, Issue 5, 2008, Pages 579-582

  Diefenbach, Konstanze ^a   Jaeger, Katrin ^a   Wollny, Agnes ^a   Penzel, Thomas ^a   Fietze, Ingo ^a   Roots, Ivar ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Anticholinergics; CYP2D6; Drug side effects; REM sleep; Sleep; Tolterodine

Indexed keywords

CYTOCHROME P450 2D6; PLACEBO; TOLTERODINE;

ADULT; ARTICLE; COGNITION; CONTROLLED STUDY; DEMOGRAPHY; DRUG METABOLISM; GENOTYPE; HETEROZYGOTE; HUMAN; HUMAN EXPERIMENT; NONREM SLEEP; NORMAL HUMAN; POLYSOMNOGRAPHY; PRIORITY JOURNAL; REM SLEEP; RETROSPECTIVE STUDY; SIDE EFFECT; SINGLE DRUG DOSE; SLEEP DISORDER; SLEEP STAGE; SLEEP TIME; STATISTICAL SIGNIFICANCE; VOLUNTEER;

ADULT; AGED; ALLELES; BENZHYDRYL COMPOUNDS; BIOTRANSFORMATION; CRESOLS; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP2D6; DOUBLE-BLIND METHOD; FEMALE; GENE DUPLICATION; GENOTYPE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PHENYLPROPANOLAMINE; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYSOMNOGRAPHY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SLEEP, REM;

EID: 45249089669     PISSN: 13899457     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.sleep.2007.07.019     Document Type: Article

References (19)

1. Nilvebrant L., Andersson K.E., Gillberg P.G., Stahl M., and Sparf B. Tolterodine-a new bladder-selective antimuscarinic agent. Eur J Pharmacol 327 (1997) 195-207
2. Hills C.J., Winter S.A., and Balfour J.A. Tolterodine. Drugs 55 (1998) 813-822
3. Clemett D., and Jarvis B. Tolterodine: a review of its use in the treatment of overactive bladder. Drugs Aging 18 (2001) 277-304
4. Brynne N., Dalen P., Alvan G., Bertilsson L., and Gabrielsson J. Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine. Clin Pharmacol Ther 63 (1998) 529-539
5. Nilvebrant L., Gillberg P.G., and Sparf B. Antimuscarinic potency and bladder selectivity of PNU-200577, a major metabolite of tolterodine. Pharmacol Toxicol 81 (1997) 169-172
6. Chapple C.R. Muscarinic receptor antagonists in the treatment of overactive bladder. Urology 55 (2000) 33-46
7. Tsao J.W., and Heilman K.M. Transient memory impairment and hallucinations associated with tolterodine use. N Engl J Med 349 (2003) 2274-2275
8. Womack K.B., and Heilman K.M. Tolterodine and memory: dry but forgetful. Arch Neurol 60 (2003) 771-773
9. Appell R. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis. Urology 50 (1997) 90-99
10. Guay D.R.P. Tolterodine, a new antimuscarinic drug for treatment of bladder overactivity. Pharmacotherapy 19 (1999) 267-280
11. Diefenbach K., Donath F., Maurer A., Quispe Bravo S., Wernecke K.D., Schwantes U., et al. Randomised, double-blind study of the effects of oxybutynin, tolterodine, trospium chloride and placebo on sleep in healthy young volunteers. Clin Drug Invest 23 (2003) 395-404
12. Diefenbach K., Arold G., Wollny A., Schwantes U., Haselmann J., and Roots I. Effects on sleep of anticholinergics used for overactive bladder treatment in healthy volunteers aged ≥ 50 years. BJU Int 95 (2005) 346-349
13. Rechtschaffen A., and Kales A. A manual of standardized terminology, techniques and scoring system for sleep stages of human sleep subjects (1968), US Government Printing Office, Washington, DC
14. Oswald W.D., and Roth E. Der Zahlen-Verbindungs-Test. Testkatalog 2000/2001 (2000), Hogrefe-Verlag, Testzentrale Göttingen Bern 35
15. Brickenkamp R., and Zillner E. The d2 test of attention (d2). Testkatalog 2000/2001 (2000), Hogrefe-Verlag, Testzentrale Göttingen Bern 60
16. Sachse C., Brockmoller J., Bauer S., and Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 60 (1997) 284-295
17. Benet L.Z., Kroetz D.L., and Sheiner L.B. Pharmacokinetics: the dynamics of drug absorption, distribution, and elimination: principle of therapeutics. In: Goodman L.S., and Gilman A.G. (Eds). The Pharmacological Basis of Therapeutics. 8th Edition (1996), McGraw-Hill, New York 3-28
18. Bradbury M.W. History and physiology of the blood-brain barrier in relation to delivery of drugs to the brain. In: Begley D.J., Bradbury M.W., and Kreuter J. (Eds). The blood-brain barrier and drug delivery to the CNS (2000), Marcel Dekker, New York, Basel 1-8
19. Nilvebrant L, Pahlman I, d'Argy, R. Tolterodine and its metabolites show very low penetration into the central nervous system. In: 29th annual meeting of the international continence society. Denver, CO; 1999, 2226 [Abstract].